Announced
Completed
Financials
Sources
Tags
Biotechnology
treatment development
biotechnology company
China
Acquisition
Cross Border
Minority
Private
Private Equity
Venture Capital
Completed
Friendly
Single Bidder
Synopsis
RTW Investments, a life science investment and innovation firm, and QIA, a global investment organization, led a $125m series B1 round in Oricell, a China-based innovative pharmaceutical company, with participation from Qiming Venture Partners and C&D Emerging Industry Equity Investment. “We are thrilled with the momentum our team has built over the last several months and look forward to using this funding to further expand our platform and research. This round reflects our investors’ recognition of Oricell’s ongoing growth and the development of our robust pipeline of ground-breaking therapeutics. We look forward to continuing to help improving the lives of patients in need,” Helen Yang, Oricell Chairman and CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.